KRAS G12C-IN-76
KRAS G12C-IN-76 (Compound 39) is an orally active KRASG12C inhibitor. KRAS G12C-IN-76 inhibits the phosphorylation of ERK. KRAS G12C-IN-76 exhibits anticancer activity against pancreatic cancer.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- CAS. Nr.: 3023465-61-1
- Formel: C38H33F4N7O2S
- Molecular Weight:727.77
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biologische Aktivität
|
KRas G12C |
KRAS G12C-IN-76 (2 h) potently inhibits ERK phosphorylation in MIA PaCa-2 KRASG12C mutant cells, with a pIC50 of 9.64[1].
KRAS G12C-IN-76 (5 days) potently inhibits the proliferation of MIA PaCa-2 KRASG12C mutant cells, with a pIC50 of 8.96[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Crl:NU(NCr)-Foxn1nu-homozygous nude (female, MIA PaCa-2 KRASG12C pancreatic cancer xenograft model)[1]
-
Dosage:50 mg/kg; 150 mg/kg
-
Administration:p.o.; daily; 17 days
-
Result:Induced 21% tumor growth regression at 50 mg/kg.
Induced 89% tumor growth regression, with complete tumor responses observed in 3 of 8 treated mice at 150 mg/kg.
Chemical Information
-
CAS. Nr. 3023465-61-1
-
Molecular Weight 727.77
-
Formel C38H33F4N7O2S
-
SMILES
F[C@@H]1C[C@@](CCC2)(COC3=NC4=C(C(N5[C@H](CN(CC5)C(/C(F)=C/C6=NC=CS6)=O)C)=N3)C=NC(C7=C8C(C#C[H])=C(C=CC8=CC=C7)F)=C4F)N2C1
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation
Verweise
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)